Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07131254 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Phase: Phase 1/2 to Early Phase 1v2 Show 5 more changesShow less
    • Start date: Sep 25, 2024 to Mar 10, 2025
    • Primary and study completion dates: Sep 24, 2027 to Dec 1, 2027
    • Eligibility criteria expanded, about 752 words
    • Secondary endpoints: 1 to 9
    • Study title expanded, about 14 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Grit Biotechnology
30 trials monitored
See 1 trial at risk
Leukemia
2,948 trials monitored
See 180 trials at risk
This study is a prospective single-arm open-label clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19 positive adult B-cell non Hodgkin lymphoma (B-NHL) and B-acute lymphoblastic leukemia (B-ALL) patients. A total of 34 subjects will be enrolled in this study.
Trial Details
NCT Number NCT07131254
Lead Sponsor Grit Biotechnology
Collaborators: Ganzhou City People's Hospital
Conditions
(from sponsor)		 Hematological Malignancy (Leukemia- Lymphoma)
Related terms Hematologic Neoplasms
Enrollment 34 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov